Ed Clarke1, Adedapo O Bashorun2, Michael Okoye2, Ama Umesi2, Mariama Badjie Hydara2, Ikechukwu Adigweme2, Rajeev Dhere3, Vistasp Sethna3, Beate Kampmann4, David Goldblatt5, Andi Tate6, Debra H Weiner7, Jorge Flores6, Mark R Alderson6, Steve Lamola6. 1. Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Road, Fajara, PO Box 273, Banjul, Gambia. Electronic address: Ed.Clarke@lshtm.ac.uk. 2. Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Road, Fajara, PO Box 273, Banjul, Gambia. 3. Serum Institute of India Pvt. Ltd., 212/2, Off Soli Poonawalla Road Hadapsar, Pune 411028, India. 4. Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Road, Fajara, PO Box 273, Banjul, Gambia; Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom. 5. Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London, 30 Guilford Street, London, United Kingdom. 6. PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, USA. 7. FHI 360, 359 Blackwell Street, Suite 200, Durham, NC, USA.
Abstract
BACKGROUND: A more affordable pneumococcal conjugate vaccine (PCV) that provides comparable protection to current PCVs is needed to ensure sustainable access in resource-limited settings. Serum Institute of India Pvt. Ltd.'s PCV candidate (SIIPL-PCV) has the potential to meet this need as manufacturing efficiency has been optimized and the vaccine targets the most prevalent disease-causing serotypes in Africa and Asia. We report SIIPL-PCV's safety, tolerability, and immunogenicity in adults, toddlers, and infants in The Gambia. METHODS: This phase 1/2, randomized, double-blind trial sequentially enrolled 34 PCV-naive adults (18-40 years old), 112 PCV (Prevenar 13® [PCV13])-primed toddlers (12-15 months old), and 200 PCV-naive infants (6-8 weeks old), who were randomized (1:1) to receive SIIPL-PCV or a licensed comparator vaccine. Infants received three-doses of SIIPL-PCV or PCV13 at 6, 10, and 14 weeks of age co-administered with routine Expanded Program on Immunization (EPI) vaccines. Reactogenicity was solicited through seven-days post-vaccination; unsolicited adverse events (AEs) were assessed throughout the study. The safety and immunogenicity of a matching booster at 10-14 months of age were evaluated in a subset of 96 infants. Immune responses were evaluated post-primary and pre- and post-booster vaccinations. RESULTS: Reactogenicity was primarily mild-to-moderate in severity. In infants, the most common solicited reactions were injection-site tenderness and fever, with no meaningful treatment-group differences. There were no serious or severe vaccine-related AEs and no meaningful trends in SAEs, vaccine-related AEs, or overall AEs. Infant post-primary seroresponse rates (IgG level ≥ 0.35 µg/mL) were ≥89% for all serotypes except 6A (79%) in the SIIPL-PCV group. IgG GMCs were >1 µg/mL for all serotypes in both SIIPL-PCV and PCV13 groups. Post-booster GMCs were comparable between groups. CONCLUSION: SIIPL-PCV was well-tolerated, had an acceptable safety profile, and was immunogenic for all vaccine serotypes. Results support the evaluation of SIIPL-PCV in a phase 3 non-inferiority trial. Clinicaltrials.gov: NCT02308540.
BACKGROUND: A more affordable pneumococcal conjugate vaccine (PCV) that provides comparable protection to current PCVs is needed to ensure sustainable access in resource-limited settings. Serum Institute of India Pvt. Ltd.'s PCV candidate (SIIPL-PCV) has the potential to meet this need as manufacturing efficiency has been optimized and the vaccine targets the most prevalent disease-causing serotypes in Africa and Asia. We report SIIPL-PCV's safety, tolerability, and immunogenicity in adults, toddlers, and infants in The Gambia. METHODS: This phase 1/2, randomized, double-blind trial sequentially enrolled 34 PCV-naive adults (18-40 years old), 112 PCV (Prevenar 13® [PCV13])-primed toddlers (12-15 months old), and 200 PCV-naive infants (6-8 weeks old), who were randomized (1:1) to receive SIIPL-PCV or a licensed comparator vaccine. Infants received three-doses of SIIPL-PCV or PCV13 at 6, 10, and 14 weeks of age co-administered with routine Expanded Program on Immunization (EPI) vaccines. Reactogenicity was solicited through seven-days post-vaccination; unsolicited adverse events (AEs) were assessed throughout the study. The safety and immunogenicity of a matching booster at 10-14 months of age were evaluated in a subset of 96 infants. Immune responses were evaluated post-primary and pre- and post-booster vaccinations. RESULTS: Reactogenicity was primarily mild-to-moderate in severity. In infants, the most common solicited reactions were injection-site tenderness and fever, with no meaningful treatment-group differences. There were no serious or severe vaccine-related AEs and no meaningful trends in SAEs, vaccine-related AEs, or overall AEs. Infant post-primary seroresponse rates (IgG level ≥ 0.35 µg/mL) were ≥89% for all serotypes except 6A (79%) in the SIIPL-PCV group. IgG GMCs were >1 µg/mL for all serotypes in both SIIPL-PCV and PCV13 groups. Post-booster GMCs were comparable between groups. CONCLUSION: SIIPL-PCV was well-tolerated, had an acceptable safety profile, and was immunogenic for all vaccine serotypes. Results support the evaluation of SIIPL-PCV in a phase 3 non-inferiority trial. Clinicaltrials.gov: NCT02308540.
Authors: Kat Franklin; Brenda Kwambana-Adams; Fernanda C Lessa; Heidi M Soeters; Laura Cooper; Matthew E Coldiron; Jason Mwenda; Martin Antonio; Tomoka Nakamura; Ryan Novak; Adam L Cohen Journal: J Infect Dis Date: 2021-09-01 Impact factor: 7.759
Authors: Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier Journal: PLoS Pathog Date: 2021-01-13 Impact factor: 6.823
Authors: Annelies Müller; Jackie Kleynhans; Linda de Gouveia; Susan Meiring; Cheryl Cohen; Lucy Jane Hathaway; Anne von Gottberg Journal: Emerg Infect Dis Date: 2022-01 Impact factor: 6.883